American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 766-777 , October 2008

Glycemic Control in Diabetic CKD Patients: Where Do We Stand?

  • Csaba P. Kovesdy, MD

      Affiliations

    • Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, VA
    • Department of Medicine, University of Virginia, Charlottesville, VA
    • Corresponding Author InformationAddress correspondence to Csaba P. Kovesdy, MD, Division of Nephrology, Salem VA Medical Center, 1970 Roanoke Blvd, Salem, VA 24153
    • ,
  • Kumar Sharma, MD

      Affiliations

    • Translational Research in Kidney Disease, University of California, San Diego, CA
    • Division of Nephrology and Hypertension, Veterans Affairs Medical Center, La Jolla, CA
    • ,
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

      Affiliations

    • Harold Simmons Center for Kidney Disease Research and Epidemiology, Torrance, CA
    • Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
    • David Geffen School of Medicine at UCLA, Torrance, CA

Received 11 January 2008 ,Accepted 1 April 2008.

References 

  1. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  2. Abbott KC, Bakris GL. Treatment of the diabetic patient: Focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002;139:289–298
  3. Friedman EA. Renal syndromes in diabetes. Endocrinol Metab Clin North Am. 1996;25:293–324
  4. Kimmel PL, Varela MP, Peterson RA, et al. Interdialytic weight gain and survival in hemodialysis patients: Effects of duration of ESRD and diabetes mellitus. Kidney Int. 2000;57:1141–1151
  5. Soubassi LP, Chiras TC, Papadakis ED, et al. Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol. 2006;38:795–800
  6. Pupim LB, Heimburger O, Qureshi AR, et al. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int. 2005;68:2368–2374
  7. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–1720
  8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  9. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005;45:A5–A7
  10. Symonds T, Berzon R, Marquis P, et al. The clinical significance of quality-of-life results: Practical considerations for specific audiences. Mayo Clin Proc. 2002;77:572–583
  11. Friedman EA, Friedman AL, Eggers P. End-stage renal disease in diabetic persons: Is the pandemic subsiding?. Kidney Int Suppl. 2006;70:S51–S54
  12. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications. 2004;18:18–26
  13. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis. 2003;41:523–531
  14. Neubaurer E. Über hyperglykaemia bei hoehricknephritis und die beziehungen zwischen glykaemie und glycosurie bein diabetes mellitus. Biochem Z. 1910;25:285–298
  15. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4–8
  16. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103–121
  17. Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75:1037–1044
  18. Mak RH, Turner C, Haycock GB, et al. Secondary hyperparathyroidism and glucose intolerance in children with uremia. Kidney Int Suppl. 1983;16:S128–S133
  19. Mak RH, Bettinelli A, Turner C, et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60:229–233
  20. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992;41:1049–1054
  21. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998;53:1353–1357
  22. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168:397–403
  23. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  24. DeFronzo RA, Tobin JD, Rowe JW, et al. Glucose intolerance in uremia (Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin). J Clin Invest. 1978;62:425–435
  25. Heaton A, Taylor R, Johnston DG, et al. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci (Lond). 1989;77:383–388
  26. McCaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985;75:391–396
  27. Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes. 1985;34:1152–1159
  28. Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: Implications for renal failure. Nephron. 1993;65:108–110
  29. Contreras I, Caro JF, Aveledo L, et al. In chronic uremia, insulin activates receptor kinase but not pyruvate dehydrogenase. Nephron. 1992;61:77–81
  30. Friedman JE, Dohm GL, Elton CW, et al. Muscle insulin resistance in uremic humans: Glucose transport, glucose transporters, and insulin receptors. Am J Physiol. 1991;261:E87–E94
  31. Ikizler TA. Protein and energy intake in advanced chronic kidney disease: How much is too much?. Semin Dial. 2007;20:5–11
  32. Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–16
  33. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311–320
  34. Lee SW, Dai G, Hu Z, et al. Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004;15:1537–1545
  35. Cano N. Bench-to-bedside review: Glucose production from the kidney. Crit Care. 2002;6:317–321
  36. Mak RH. Insulin resistance in uremia: Effect of dialysis modality. Pediatr Res. 1996;40:304–308
  37. Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564–567
  38. Balaskas EV, Rodela H, Oreopoulos DG. Effects of intraperitoneal infusion of dextrose and amino acids on the appetite of rabbits. Perit Dial Int. 1993;13(suppl 2):S490–S498
  39. Mamoun AH, Anderstam B, Sodersten P, et al. Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int. 1996;49:1276–1282
  40. Walls EK, Koopmans HS. Differential effects of intravenous glucose, amino acids, and lipid on daily food intake in rats. Am J Physiol. 1992;262:R225–R234
  41. Yin TH, Tsai WH, Barone FC, et al. Effects of continuous intramesenteric infusion of glucose and amino acids on food intake in rats. Physiol Behav. 1979;22:1207–1210
  42. von BH, Gahl GM, Riedinger H, et al. Adaptation of CAPD patients to the continuous peritoneal energy uptake. Kidney Int. 1983;23:29–34
  43. Skutches CL, Sigler MH. Plasma glucose turnover and oxidation during hemodialysis: Nutritional effect of dialysis fluid. Am J Clin Nutr. 1997;65:128–135
  44. Kopple JD, Swendseid ME, Shinaberger JH, et al. The free and bound amino acids removed by hemodialysis. Trans Am Soc Artif Intern Organs. 1973;19:309–313
  45. Tzamaloukas AH. The use of glycosylated hemoglobin in dialysis patients. Semin Dial. 1998;11:141–143
  46. Friedman EA. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant. 1999;14(suppl 3):S1–S9
  47. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–2569
  48. Fluckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med. 1981;304:823–827
  49. Goldstein DE. Is glycosylated hemoglobin clinically useful?. N Engl J Med. 1984;310:384–385
  50. Tzamaloukas AH. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Perit Dial. 1996;12:171–175
  51. Tzamaloukas AH, Hsi KC, Quintana BJ, et al. Glycosylated hemoglobin measured by affinity chromatography in diabetic and nondiabetic patients on long-term dialysis therapy. West J Med. 1989;150:415–419
  52. Morgan LJ, Marenah CB, Morgan AG, et al. Glycated haemoglobin and fructosamine in non-diabetic subjects with chronic renal failure. Nephrol Dial Transplant. 1990;5:868–873
  53. Tiran A, Pieber T, Tiran B, et al. [Photometric determination of HbA1c levels in clinical practice]. Dtsch Med Wochenschr. 1994;119:833–836
  54. De MS, Cecchin E, Camurri C, et al. Origin of glycosylated hemoglobin A1 in chronic renal failure. Int J Artif Organs. 1983;6:77–82
  55. Sabater J, Quereda C, Herrera I, et al. Nonenzymatic glycosylation of hemoglobin and total plasmatic proteins in end-stage renal disease. Am J Nephrol. 1991;11:37–43
  56. Wettre S, Lundberg M. Kinetics of glycosylated haemoglobin in uraemia determined on ion-exchange and affinity chromatography: No increase in the rate of glycosylation. Diabetes Res. 1986;3:107–110
  57. Paisey R, Banks R, Holton R, et al. Glycosylated haemoglobin in uraemia. Diabet Med. 1986;3:445–448
  58. Lamb E, Venton TR, Cattell WR, et al. Serum glycated albumin and fructosamine in renal dialysis patients. Nephron. 1993;64:82–88
  59. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903
  60. Constanti C, Simo JM, Joven J, et al. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: The influence of hypoalbuminaemia and hypergammaglobulinaemia. Ann Clin Biochem. 1992;29(Pt 4):437–442
  61. Ford HC, Lim WC, Crooke MJ. Hemoglobin A1 and serum fructosamine levels in hyperthyroidism. Clin Chim Acta. 1987;166:317–321
  62. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus (The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study). J Diabetes Complications. 1994;8:13–17
  63. Wainai H, Katsukawa F, Takei I, et al. Influence of glycemic control and hypertension on urinary microprotein excretion in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1991;5:160–161
  64. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  65. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341:1306–1309
  66. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–709
  67. Gilbert RE, Tsalamandris C, Bach LA, et al. Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int. 1993;44:855–859
  68. Hasslacher C, Bostedt-Kiesel A, Kempe HP, et al. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1051–1056
  69. Mulec H, Blohme G, Grande B, et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant. 1998;13:651–655
  70. Ravid M, Savin H, Lang R, et al. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus (A 14-year follow-up report on 195 patients). Arch Intern Med. 1992;152:1225–1229
  71. Viberti GC, Bilous RW, Mackintosh D, et al. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br Med J. 1983;286:598–602
  72. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75
  73. Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia. 1983;25:496–501
  74. Kussman MJ, Goldstein H, Gleason RE. The clinical course of diabetic nephropathy. JAMA. 1976;236:1861–1863
  75. Knowles HC. Long-term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Physicians. 1971;84:95–101
  76. Parving HH, Jacobsen P, Rossing K, et al. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int. 1996;49:1778–1782
  77. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996;313:779–784
  78. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294–2303
  79. Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556–3565
  80. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  81. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  82. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591
  83. Menon V, Greene T, Pereira AA, et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol. 2005;16:3411–3417
  84. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  85. Kovesdy CP, Trivedi BK, Anderson JE. Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort study. Adv Chronic Kidney Dis. 2006;13:183–188
  86. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Assocation between glycemic control and mortality in diabetic patients with chronic kidney disease stage 1-5 not yet on dialysis. J Am Soc Nephrol. 2007;18:573A;(abstr)
  87. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:4–7
  88. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728–2735
  89. Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105–2110
  90. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909–913
  91. McMurray SD, Johnson G, Davis S, et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002;40:566–575
  92. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. Diabetes Care. 2006;29:1496–1500
  93. Williams ME, Lacson E, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–1509
  94. Tzamaloukas AH, Yuan ZY, Murata GH, et al. Clinical associations of glycemic control in diabetics on CAPD. Adv Perit Dial. 1993;9:291–294
  95. Tzamaloukas AH, Murata GH, Zager PG, et al. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J. 1993;39:880–885
  96. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–1055
  97. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50:865–879
  98. Krolewski AS, Laffel LM, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251–1255
  99. The absence of a glycemic threshold for the development of long-term complications. The perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–1298
  100. American Diabetes Association. Standards of Medical Care in Diabetes—2008. Diabetes Care. 2008;31(suppl 1):S12–S54
  101. Goff DC, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol. 2007;99:4i–20i
  102. Williams ME, Roshan B. Role of the new oral hypoglycemic drugs in the diabetic patient with ESRD. Semin Dial. 1999;12:25–31
  103. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46:797–806
  104. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615–1625
  105. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C beta inhibition. Am J Kidney Dis. 2003;42:456–465
  106. Toyoda M, Suzuki D, Honma M, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66:1107–1114
  107. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686–2690
  108. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188–2197
  109. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005;27:1164–1180
  110. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis. 2000;35:365–380
  111. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(suppl 1):S100–S106
  112. Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(suppl 3):S254–S258
  113. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005;62:1671–1681
  114. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605–614
  115. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vasc Pharmacol. 2006;44:309–315
  116. Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45:522–530
  117. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97:8015–8020
  118. McGowan TA, Zhu Y, Sharma K. Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy. Curr Diabetes Rep. 2004;4:447–454
  119. Wenzel R, Mann J, Jurgens C, et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in participants with diabetic nephropathy. J Am Soc Nephrol. 2005;16:58A;(abstr)
  120. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: Implications for treatment. Semin Nephrol. 2007;27:153–160
  121. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239–S243

 Originally published online as doi:10.1053/j.ajkd.2008.04.011 on June 20, 2008.

PII: S0272-6386(08)00769-5

doi: 10.1053/j.ajkd.2008.04.011

American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 766-777 , October 2008

Article Tools

* Image Usage & Resolution